Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Forum: journal club.

Cytometry

Fattorossi A, Battaglia A, Maggiano N, Malinconico P, Andreocci L, Mancuso S, Scambia G.
PMID: 10797452
Cytometry. 2000 Apr 15;42(2):126.

No abstract available.

Cite
Fattorossi A, Battaglia A, Maggiano N, et al. Forum: journal club. Cytometry. 2000;42(2):126
Fattorossi, A., Battaglia, A., Maggiano, N., Malinconico, P., Andreocci, L., Mancuso, S., & Scambia, G. (2000). Forum: journal club. Cytometry, 42(2), 126.
Fattorossi, et al. "Forum: journal club." Cytometry vol. 42,2 (2000): 126.
Fattorossi A, Battaglia A, Maggiano N, Malinconico P, Andreocci L, Mancuso S, Scambia G. Forum: journal club. Cytometry. 2000 Apr 15;42(2):126. PMID: 10797452.
Copy Download .nbib Format: NLM
Autism Spectrum Disorders and the Gut Microbiota.

Nutrients

Fattorusso A, Di Genova L, Dell'Isola GB, Mencaroni E, Esposito S.
PMID: 30823414
Nutrients. 2019 Feb 28;11(3). doi: 10.3390/nu11030521.

In recent years, there has been an emerging interest in the possible role of the gut microbiota as a co-factor in the development of autism spectrum disorders (ASDs), as many studies have highlighted the bidirectional communication between the gut...

Cite
Fattorusso A, Di Genova L, Dell'Isola GB, et al. Autism Spectrum Disorders and the Gut Microbiota. Nutrients. 2019;11(3)doi: 10.3390/nu11030521.
Fattorusso, A., Di Genova, L., Dell'Isola, G. B., Mencaroni, E., & Esposito, S. (2019). Autism Spectrum Disorders and the Gut Microbiota. Nutrients, 11(3), . https://doi.org/10.3390/nu11030521
Fattorusso, Antonella, et al. "Autism Spectrum Disorders and the Gut Microbiota." Nutrients vol. 11,3 (2019). doi: https://doi.org/10.3390/nu11030521
Fattorusso A, Di Genova L, Dell'Isola GB, Mencaroni E, Esposito S. Autism Spectrum Disorders and the Gut Microbiota. Nutrients. 2019 Feb 28;11(3). doi: 10.3390/nu11030521. PMID: 30823414; PMCID: PMC6471505.
Copy Download .nbib Format: NLM
Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer.

Translational oncology

Martinelli E, Fattorossi A, Battaglia A, Petrillo M, Raspaglio G, Zannoni GF, Fanelli M, Gallo D, Scambia G.
PMID: 29448203
Transl Oncol. 2018 Apr;11(2):358-365. doi: 10.1016/j.tranon.2018.01.016. Epub 2018 Feb 20.

Class III β-tubulin (TUBB3) overexpression in ovarian cancer (OC) associates with poor prognosis. We investigated whether TUBB3 overexpression elicited anti-TUBB3 antibody production in OC patients and whether these antibodies may have diagnostic and prognostic impact. The presence of serum...

Cite
Martinelli E, Fattorossi A, Battaglia A, et al. Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer. Transl Oncol. 2018;11(2):358-365doi: 10.1016/j.tranon.2018.01.016.
Martinelli, E., Fattorossi, A., Battaglia, A., Petrillo, M., Raspaglio, G., Zannoni, G. F., Fanelli, M., Gallo, D., & Scambia, G. (2018). Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer. Translational oncology, 11(2), 358-365. https://doi.org/10.1016/j.tranon.2018.01.016
Martinelli, Enrica, et al. "Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer." Translational oncology vol. 11,2 (2018): 358-365. doi: https://doi.org/10.1016/j.tranon.2018.01.016
Martinelli E, Fattorossi A, Battaglia A, Petrillo M, Raspaglio G, Zannoni GF, Fanelli M, Gallo D, Scambia G. Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer. Transl Oncol. 2018 Apr;11(2):358-365. doi: 10.1016/j.tranon.2018.01.016. Epub 2018 Feb 20. PMID: 29448203; PMCID: PMC5852414.
Copy Download .nbib Format: NLM
The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies.

Frontiers in neurology

Fattorusso A, Matricardi S, Mencaroni E, Dell'Isola GB, Di Cara G, Striano P, Verrotti A.
PMID: 34239494
Front Neurol. 2021 Jun 22;12:674483. doi: 10.3389/fneur.2021.674483. eCollection 2021.

Epilepsy is one of the most common neurological chronic disorders, with an estimated prevalence of 0. 5 - 1%. Currently, treatment options for epilepsy are predominantly based on the administration of symptomatic therapy. Most patients are able to achieve...

Cite
Fattorusso A, Matricardi S, Mencaroni E, et al. The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies. Front Neurol. 2021;12:674483doi: 10.3389/fneur.2021.674483.
Fattorusso, A., Matricardi, S., Mencaroni, E., Dell'Isola, G. B., Di Cara, G., Striano, P., & Verrotti, A. (2021). The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies. Frontiers in neurology, 12674483. https://doi.org/10.3389/fneur.2021.674483
Fattorusso, Antonella, et al. "The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies." Frontiers in neurology vol. 12 (2021): 674483. doi: https://doi.org/10.3389/fneur.2021.674483
Fattorusso A, Matricardi S, Mencaroni E, Dell'Isola GB, Di Cara G, Striano P, Verrotti A. The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies. Front Neurol. 2021 Jun 22;12:674483. doi: 10.3389/fneur.2021.674483. eCollection 2021. PMID: 34239494; PMCID: PMC8258148.
Copy Download .nbib Format: NLM
PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients.

Cancers

Battaglia A, Piermattei A, Buzzonetti A, Pasciuto T, Zampetti N, Fossati M, Angelico G, Iacobelli V, Nero C, Iannucci V, Scambia G, Fagotti A, Fattorossi A.
PMID: 34680346
Cancers (Basel). 2021 Oct 16;13(20). doi: 10.3390/cancers13205200.

BACKGROUND: Ovarian cancer (OC) has recently attracted attention for the use of PD-1/PD-L1 axis blocking agents, with durable activity reported only in a subset of patients. The most used biomarker for sensitivity to the PD-1/PD-L1 axis blockade is tumour...

Cite
Battaglia A, Piermattei A, Buzzonetti A, et al. PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients. Cancers (Basel). 2021;13(20)doi: 10.3390/cancers13205200.
Battaglia, A., Piermattei, A., Buzzonetti, A., Pasciuto, T., Zampetti, N., Fossati, M., Angelico, G., Iacobelli, V., Nero, C., Iannucci, V., Scambia, G., Fagotti, A., & Fattorossi, A. (2021). PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients. Cancers, 13(20), . https://doi.org/10.3390/cancers13205200
Battaglia, Alessandra, et al. "PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients." Cancers vol. 13,20 (2021). doi: https://doi.org/10.3390/cancers13205200
Battaglia A, Piermattei A, Buzzonetti A, Pasciuto T, Zampetti N, Fossati M, Angelico G, Iacobelli V, Nero C, Iannucci V, Scambia G, Fagotti A, Fattorossi A. PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients. Cancers (Basel). 2021 Oct 16;13(20). doi: 10.3390/cancers13205200. PMID: 34680346; PMCID: PMC8534085.
Copy Download .nbib Format: NLM
Unexpected interference in cell surface staining by monoclonal antibodies to unrelated antigens.

Cytometry. Part B, Clinical cytometry

De Vita M, Catzola V, Buzzonetti A, Fossati M, Battaglia A, Zamai L, Fattorossi A.
PMID: 25270399
Cytometry B Clin Cytom. 2014 Oct 01; doi: 10.1002/cytob.21197. Epub 2014 Oct 01.

Background: The possible occurrence of an erroneous immunophenotyping due to interference between monoclonal antibodies (MoAbs) is often overlooked when the epitopes are assumed to be not close to each other. This is particularly important when exploring immune cell populations...

Cite
De Vita M, Catzola V, Buzzonetti A, et al. Unexpected interference in cell surface staining by monoclonal antibodies to unrelated antigens. Cytometry B Clin Cytom. 2014;doi: 10.1002/cytob.21197.
De Vita, M., Catzola, V., Buzzonetti, A., Fossati, M., Battaglia, A., Zamai, L., & Fattorossi, A. (2014). Unexpected interference in cell surface staining by monoclonal antibodies to unrelated antigens. Cytometry. Part B, Clinical cytometry, . https://doi.org/10.1002/cytob.21197
De Vita, Martina, et al. "Unexpected interference in cell surface staining by monoclonal antibodies to unrelated antigens." Cytometry. Part B, Clinical cytometry vol. (2014). doi: https://doi.org/10.1002/cytob.21197
De Vita M, Catzola V, Buzzonetti A, Fossati M, Battaglia A, Zamai L, Fattorossi A. Unexpected interference in cell surface staining by monoclonal antibodies to unrelated antigens. Cytometry B Clin Cytom. 2014 Oct 01; doi: 10.1002/cytob.21197. Epub 2014 Oct 01. PMID: 25270399.
Copy Download .nbib Format: NLM
Regulation of normal human polyrnorphonuclear leucocytes by carnitine.

Mediators of inflammation

Fattorossi A, Biselli R, Casciaro A, Tzantzoglou S, de Simone C.
PMID: 18475569
Mediators Inflamm. 1993;2(7):S37-41. doi: 10.1155/S0962935193000742.

The effect of carnitine, a drug that plays an essential role in mitochondria metabolism, on some of the most important human polymorphonuclear leucocytes (PMN) activation steps including modulation of adhesion molecule density, reactive oxygen species production, and tumour necrosis...

Cite
Fattorossi A, Biselli R, Casciaro A, et al. Regulation of normal human polyrnorphonuclear leucocytes by carnitine. Mediators Inflamm. 1993;2(7):S37-41doi: 10.1155/S0962935193000742.
Fattorossi, A., Biselli, R., Casciaro, A., Tzantzoglou, S., & de Simone, C. (1993). Regulation of normal human polyrnorphonuclear leucocytes by carnitine. Mediators of inflammation, 2(7), S37-41. https://doi.org/10.1155/S0962935193000742
Fattorossi, A, et al. "Regulation of normal human polyrnorphonuclear leucocytes by carnitine." Mediators of inflammation vol. 2,7 (1993): S37-41. doi: https://doi.org/10.1155/S0962935193000742
Fattorossi A, Biselli R, Casciaro A, Tzantzoglou S, de Simone C. Regulation of normal human polyrnorphonuclear leucocytes by carnitine. Mediators Inflamm. 1993;2(7):S37-41. doi: 10.1155/S0962935193000742. PMID: 18475569; PMCID: PMC2365451.
Copy Download .nbib Format: NLM
Correction to: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients.

Cancer immunology, immunotherapy : CII

Battaglia A, Buzzonetti A, Fossati M, Scambia G, Fattorossi A, Madiyalakan MR, Mahnke YD, Nicodemus C.
PMID: 32219502
Cancer Immunol Immunother. 2020 Jul;69(7):1389. doi: 10.1007/s00262-020-02537-4.

The original version of this article unfortunately contained a mistake.

Cite
Battaglia A, Buzzonetti A, Fossati M, et al. Correction to: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients. Cancer Immunol Immunother. 2020;69(7):1389doi: 10.1007/s00262-020-02537-4.
Battaglia, A., Buzzonetti, A., Fossati, M., Scambia, G., Fattorossi, A., Madiyalakan, M. R., Mahnke, Y. D., & Nicodemus, C. (2020). Correction to: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients. Cancer immunology, immunotherapy : CII, 69(7), 1389. https://doi.org/10.1007/s00262-020-02537-4
Battaglia, Alessandra, et al. "Correction to: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients." Cancer immunology, immunotherapy : CII vol. 69,7 (2020): 1389. doi: https://doi.org/10.1007/s00262-020-02537-4
Battaglia A, Buzzonetti A, Fossati M, Scambia G, Fattorossi A, Madiyalakan MR, Mahnke YD, Nicodemus C. Correction to: Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients. Cancer Immunol Immunother. 2020 Jul;69(7):1389. doi: 10.1007/s00262-020-02537-4. PMID: 32219502.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries